

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : A61K 9/22, 9/52, 9/70, 31/135, A61P 13/10		A1	(11) International Publication Number: WO 00/12069
			(43) International Publication Date: 9 March 2000 (09.03.00)
(21) International Application Number: PCT/SE99/01463		backen 26, S-117 65 Stockholm (SE). WIKBERG, Martin [SE/SE]; Torvmossevägen 14, S-429 32 Kullavik (SE).	
(22) International Filing Date: 26 August 1999 (26.08.99)		(74) Agents: WIDÉN, Björn et al.; Pharmacia & Upjohn AB, S-112 87 Stockholm (SE).	
(30) Priority Data: 9802864-0 27 August 1998 (27.08.98) SE 9803871-4 11 November 1998 (11.11.98) SE		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(71) Applicant (for all designated States except US): PHARMACIA & UPJOHN AB [SE/SE]; S-112 87 Stockholm (SE).		Published With international search report. With amended claims.	
(72) Inventors; and (75) Inventors/Applicants (for US only): NILVEBRANT, Lisbeth [SE/SE]; Lillsjönäsvägen 11, S-167 35 Bromma (SE). HALLÉN, Bengt [SE/SE]; Västervägen 8A, S-191 49 Sollentuna (SE). OLSSON, Birgitta [SE/SE]; Ekeberga, S-179 92 Stenhamra (SE). STRÖMBOM, Jan [SE/SE]; Brukgårdarna 18, S-743 50 Vattholma (SE). KREILGÅRD, Bo [DK/DK]; Smedievej 18, DK-3400 Hillerød (DK). ORUP JACOBSEN, Lene [DK/DK]; Brogårdsvej 105, DK-2820 Gentofte (DK). HOECK, Ulla [DK/DK]; Kighusvaenget 7, DK-3400 Hillerød (DK). KRISTENSEN, Helle [DK/DK]; Lindegårds Allé 16, DK-3550 Slangerup (DK). GREN, Torkel [SE/SE]; Funbo, Skogsängen, S-755 97 Uppsala (SE). RINGBERG, Anders [SE/SE]; Grenljus-			
(54) Title: THERAPEUTIC FORMULATION FOR ADMINISTERING TOLTERODINE WITH CONTROLLED RELEASE			
(57) Abstract A method and formulation for treating unstable or overactive urinary bladder, wherein tolterodine or a tolterodine-related compound, or a pharmaceutically acceptable salt thereof, is administered to a patient in a pharmaceutically effective amount thereof through a controlled release formulation that administers tolterodine or said tolterodine-related compound, or salt thereof, at a controlled rate for at least 24 hours.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

Descripti n

5

10

15

20

25

30

35

40

45

50

55

THERAPEUTIC FORMULATION FOR ADMINISTERING TOLTERODINE WITH CONTROLLED RELEASE

The present invention relates to an improved method of treating unstable or overactive urinary bladder as well as a formulation therefor.

A substantial part (5-10%) of the adult population suffers from urinary incontinence, and the prevalence, particularly of so-called urge incontinence, increases with age. The symptoms of an unstable or overactive bladder comprise urge incontinence, urgency and urinary frequency. It is assumed that unstable or overactive bladder is caused by uncontrolled contractions of the bundles of smooth muscle fibres forming the muscular coat of the urinary bladder (the detrusor muscle) during the filling phase of the bladder. These contractions are mainly controlled by cholinergic muscarinic receptors, and the pharmacological treatment of unstable or overactive bladder has been based on muscarinic receptor antagonists. The drug of choice has for a long time been oxybutynin.

Oxybutynin, which chemically is the DL-racemic form of 4-diethylamino-2-butyryl-phenylcyclohexylglycolate, is given orally, usually as a tablet or syrup. Oxybutynin, usually administered as the chloride salt, is metabolized to an active metabolite, N-desethyl-oxybutynin. The drug is rapidly absorbed from the gastrointestinal tract following administration and has a duration of from three to six hours. While the effectiveness of oxybutynin has been well documented, its usefulness is limited by classical antimuscarinic side-effects, particularly dry mouth, which often leads to discontinuation of treatment.

WO 96/12477 discloses a controlled release delivery system for oxybutynin, which delivery system is said not only to be of convenience to the patient by reducing the administration to a once daily regimen, but also to reduce adverse side-effects by limiting the initial peak concentrations of oxybutynin and active metabolite in the blood of the patient.

5
10
15
20
25
30
35
40
45
50
55

The alleged relief of side-effects by reducing or eliminating peak concentrations through administration of the controlled release delivery system is, however, contradicted by a later published clinical report, Nilsson, C. G., et al., *Neurourology and Urodynamics* 16 (1997) 533-542, which describes clinical tests performed with the controlled release delivery system disclosed in WO 96/12477 above. In the clinical tests reported, a 10 mg controlled release oxybutynin tablet was compared with the administration of a conventional (immediate release) 5 mg tablet given twice daily to urge incontinent patients. While high peak levels of the drug obviously were eliminated with the controlled release oxybutynin tablet, no difference in side-effects between the controlled release tablet and the conventional tablet was observed. The advantage of the controlled release tablet thus resided merely in enhancing treatment compliance by its once-a-day dosage rather than also reducing side-effects as stated in WO 96/12477.

20
25
30
35
40
45
50
55

Recently, an improved muscarinic receptor antagonist, tolterodine, (R)-N,N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropanamine, has been marketed for the treatment of urge incontinence and other symptoms of unstable or overactive urinary bladder. Both tolterodine and its major, active metabolite, the 5-hydroxymethyl derivative of tolterodine, which significantly contributes to the therapeutic effect, have considerably less side-effects than oxybutynin, especially regarding the propensity to cause dry mouth. While tolterodine is equipotent with oxybutynin in the bladder, its affinity for muscarinic receptors of the salivary gland is eight times lower than that of oxybutynin; see, for example, Nilvebrant, L., et al., *European Journal of Pharmacology* 327 (1997) 195-207. The selective effect of tolterodine in humans is described in Stahl, M. M. S., et al., *Neurourology and Urodynamics* 14 (1995) 647-655, and Bryne, N., *International Journal of Clinical Pharmacology and Therapeutics*, Vol. 35, No. 7 (1995) 287-295.

5 The currently marketed administration form of
10 tolterodine is filmcoated tablets containing 1 mg or 2 mg
of tolterodine L-tartrate for immediate release in the
gastrointestinal tract, the recommended dosage usually
5 being 2 mg twice a day. While, as mentioned, the side-
effects, such as dry mouth, are much lower than for
oxybutynin, they still exist, especially at higher dosages.

15 According to the present invention it has now
surprisingly been found that, contrary to the case of
10 oxybutynin, the substantial elimination of peak serum
levels of tolterodine and its active metabolite through
20 controlled release of tolterodine for an extended period of
time, such as through a once-daily administration form,
while maintaining the desired effect on the bladder, indeed
15 gives a significant reduction of the (already low) side-
effects, particularly dry mouth, compared with those
25 obtained for the same total dosage of immediate release
tablets over the same period. In other words, eliminating
the peak serum levels of the active moiety affects the
30 adverse effects, and particularly dry mouth, more than the
desired effect on the detrusor activity, simultaneously as
the flattening of the serum concentration does not lead to
loss of activity or increased incidence of urinary
35 retention or other safety concerns. Thus, in addition to
25 the convenience advantage of controlled release
administration, one may either (i) for a given total dosage
of tolterodine, reduce the side-effects, such as dry mouth,
40 or (ii) for a given level of acceptable side-effects,
increase the dosage of tolterodine to obtain an increased
30 effect on the bladder, if desired.

45 In one aspect, the present invention therefore
provides a method of treating unstable or overactive
urinary bladder, which method comprises administering to a
(mammal) patient in need of such treatment tolterodine or a
35 tolterodine-related compound, or a pharmaceutically
acceptable salt thereof, through a controlled release
50 formulation that administers tolterodine or said
tolterodine-related compound, or salt thereof, at a

5 controlled rate for at least 24 hours. It is preferred that
the dosage form formulation is capable of maintaining a
substantially constant serum level of the active moiety or
10 moieties for said at least 24 hours.

5 Overactive urinary bladder encompasses detrusor
instability, detrusor hyperreflexia, urge incontinence,
urgency and urinary frequency.

15 As mentioned above, the chemical name of tolterodine
is (R)-N,N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-
10 phenylpropanamine. The term "tolterodine-related compound"
is meant to encompass the major, active metabolite of
tolterodine, i.e. (R)-N,N-diisopropyl-3-(2-hydroxy-5-
20 hydroxymethylphenyl)-3-phenylpropanamine; the corresponding
(S)-enantiomer to tolterodine, i.e. (S)-N,N-diisopropyl-3-
15 (2-hydroxy-5-methylphenyl)-3-phenylpropanamine; the 5-
hydroxymethyl metabolite of the (S)-enantiomer, i.e. (S)-
25 N,N-diisopropyl-3-(2-hydroxy-5-hydroxymethylphenyl)-3-
phenylpropanamine; as well as the corresponding racemate to
tolterodine, i.e. (R,S)-N,N-diisopropyl-3-(2-hydroxy-5-
20 methylphenyl)-3-phenylpropanamine; and prodrug forms
thereof.

30 By the term "active moiety or moities" is meant the
sum of free or unbound (i.e. not protein bound)
concentrations of (i) tolterodine and active metabolite
35 thereof, when tolterodine (or prodrug form) is
25 administered; or (ii) tolterodine and active metabolite
thereof and/or (S)-enantiomer to tolterodine and active
metabolite thereof, when the corresponding racemate (or
40 prodrug form) is administered; or (iii) active metabolite,
30 when the (R)-5-hydroxymethyl metabolite of tolterodine (or
prodrug form) is administered; or (iv) (S)-enantiomer to
tolterodine and active metabolite thereof, when the (S)-
45 enantiomer (or prodrug) is administered; or (v) active (S)-
metabolite, when the (S)-5-hydroxymethyl metabolite is
35 administered.

50 The term "substantially constant" with respect to the
serum level of active moiety or moities means that the
release profile of the controlled release formulation

5 should essentially not exhibit any peak values. This may,
more sophisticatedly, also be expressed by reference to the
10 "flucuation index" (FI) for the serum concentration of
(unbound) active moiety (or sum of active moities when
5 relevant), where the fluctuation index FI is calculated as

$$FI = (C_{max} - C_{min}) / AUC_{\tau} / \tau$$

15 wherein C_{max} and C_{min} are the maximum and minimum
10 concentrations, respectively, of active moiety, AUC_{τ} is the
area under the serum concentration profile (concentration
20 vs time curve) for dosage interval τ , and τ is the length
of the dosage interval. Thus, according to the present
invention, the controlled release formulation should
15 provide a mean fluctuation index (for n being at least 30)
that is usually not higher than about 2.0, more preferably
25 not higher than about 1.5, particularly not higher than
about 1.0, for example not higher than about 0.8.

For tolterodine and its 5-hydroxymethyl metabolite,
30 the 24-hour exposure, expressed as AUC unbound active
moiety (tolterodine plus metabolite) is usually in the
range of from about 5 to about 150 nM*h, preferably from
about 10 to about 120 nM*h, depending on the dosage needed
35 by the particular patient. The indicated limits are based
25 upon calculation of the unbound concentrations of active
moiety assuming a fraction unbound of 3.7% for tolterodine
and 36% for the 5-hydroxymethyl metabolite (Nilvebrant, L.,
et al., Life Sciences, Vol. 60, Nos. 13/14 (1997) 1129-
40 1136).

30 Correspondingly, for tolterodine and its 5-
hydroxymethyl metabolite, the average (blood) serum or
plasma levels are usually in the range of about 0.2 to
45 about 6.3 nM, preferably in the range of about 0.4 to about
5.0 nM.

35 Tolterodine, its corresponding (S)-enantiomer and
racemate and the preparation thereof are described in e.g.
50 WO 89/06644. For a description of the active (R)-5-
hydroxymethyl metabolite of tolterodine (as well as the

(S)-5-hydroxymethyl metabolite), it may be referred to WO 94/11337. The (S)-enantiomer and its use in the treatment of urinary and gastrointestinal disorders is described in WO 98/03067.

In another aspect, the present invention provides a pharmaceutical formulation containing tolterodine or a tolterodine-related compound, or a pharmaceutically acceptable salt thereof, which formulation when administered to a patient provides controlled release of tolterodine or said tolterodine-related compound, or salt thereof, for at least 24 hours, preferably such that a substantially constant serum level of the active moiety or moieties is maintained for said at least 24 hours.

Still another aspect of the present invention provides the use of tolterodine or a tolterodine-related compound, or a pharmaceutically acceptable salt thereof, for the manufacture of a therapeutical formulation for treating unstable or overactive urinary bladder, which formulation provides a controlled release of tolterodine or said tolterodine-related compound, or salt thereof at a controlled rate for at least 24 hours, preferably such that a substantially constant serum level of the active moiety or moieties is maintained for said at least 24 hours.

The controlled release formulation is preferably an oral delivery system or a transdermal preparation, such as a transdermal patch, but also other controlled release forms may, of course, be contemplated, such as buccal tablets, rectal suppositories, subcutaneous implants, formulations for intramuscular administration.

An exemplary type of oral controlled release formulation, a specific embodiment of which is described in Example 1 below, is a multi-unit formulation comprising controlled-release beads. Each bead comprises (i) a core unit of a water-soluble, water-swellaable or water-insoluble inert material (having a size of about 0.05 to 2 about 2 mm), such as e.g. a sucrose sphere; (ii) a first layer on the core of a substantially water-insoluble (often hydrophilic) polymer (this layer may be omitted in the case

of an insoluble core, such as e.g. of silicon dioxide),
(iii) a second layer of a water-soluble polymer having an
active ingredient dissolved or dispersed therein, and (iv)
a third polymer layer effective for controlled release of
the active ingredient (e.g. a water-insoluble polymer in
combination with a water-soluble polymer).

In the case of an oral controlled release formulation
for once-daily administration, the dosage of tolterodine
(or tolterodine related compound) is, for example, 4 mg or
6 mg.

A transdermal patch for tolterodine or tolterodine-
related compound is described in our co-pending
international application "Transdermally administered
tolterodine as antimuscarinic agent for the treatment of
overactive bladder" (based on Swedish patent application
no. 9802864-0, filed on 27 August 1998), the full
disclosure of which is incorporated by reference herein.
Illustrative patch formulations are described in Example 2
below.

With the guidance of the disclosure herein, the
skilled person may either adapt controlled release
administration forms, such as tablets, capsules, patches
etc, known in the art, to obtain the objectives of the
present invention, or design modified or new controlled
release administration forms.

The invention is illustrated by the following
Examples, without, however, limiting the scope of the
invention in any way. Percentages are by weight, unless
otherwise stated. Reference will be made to the
accompanying drawings, in which:

Figure 1 is a diagram showing the variation of serum
concentration (nmol/L) of (unbound) active moiety with time
(hours) during 24 hours when administering a predetermined
total dosage of tolterodine (4 mg) through (i) an immediate
release tablet (2 mg) twice daily as in the prior art, and
(ii) a controlled release capsule (4 mg) once daily in
accordance with the present invention;

Figure 2 is a diagram showing the variation of the basal salivation (g/min) with time (hours) during 4 hours after administration of (i) a 4 mg tolterodine controlled release capsule in accordance with the present invention, (ii) a prior art tolterodine immediate release tablet, and (iii) placebo; and

Figure 3 is a bar chart diagram showing patients' individual estimates of experienced dry mouth side effect (no dry mouth, mild, moderate, severe) after administration of tolterodine through (i) a conventional 2 mg immediate release tablet, (ii) controlled release capsules of 4, 6 and 8 mg, respectively, according to the present invention, and (iii) placebo.

EXAMPLE 1

TOLTERODINE ORAL CR CAPSULE AND IR TABLET

Preparation of tolterodine CR capsules 2 mg and 4 mg

A controlled release (CR) capsule containing non-pareil beads coated by (i) an ethylcellulose layer, (ii) a tolterodine/HPMC layer, and (iii) a sustained release ethylcellulose/HPMC layer was prepared as follows:

1200 g of (starch-containing) sugar spheres, 20-25 mesh, were charged into a Wurster fluid bed and sequentially coated with the following three coating solutions:

- (1) a Surelease® sealcoating solution prepared by mixing 788 g of Surelease® with 563 g of purified water (Surelease® is an aqueous filmcoating dispersion, about 25% solids, consisting primarily of ethylcellulose plasticized with fractionated coconut oil; manufactured by Colorcon, Inc., West Point, PA, U.S.A.);
- (2) a suspension prepared by first dissolving 35.0 g of tolterodine L-tartrate in 2190 g of purified water, and then mixing the solution with 6.6 g of Hypromellose, 5cP (hydroxypropylmethyl cellulose (HPMC)); and

5

- (3) a sustained release coating solution prepared by mixing 29 g of Hypromellose, 5 cP, with 375 g of purified water, and then mixing with 695 g of Surelease®.

10

After drying, the coated spheres were filled into hard gelatin capsule shells (size 3, white/white) to obtain 2 mg and 4 mg capsules, respectively, of the composition (filling mass for 2 mg capsule, 169-207 mg/capsule):

15

	<u>2 mg capsule</u>	<u>4 mg capsule</u>
10 Tolterodine L-tartrate	2.0 mg	4.0 mg
sugar spheres, 20-25 mesh	69 mg	137 mg
20 Surelease®	21 mg	42 mg
Hypromellose, 5cP	2.0 mg	4.1 mg

15 **Tolterodine L-tartrate IR tablets 2 mg**

25

Commercially available tolterodine L-tartrate 2 mg tablets for immediate release (IR) (Detrusitol®, Pharmacia & Upjohn AB, Sweden) were used. The tablets had the following composition:

20

30

Core

Tolterodine L-tartrate	2.0 mg
cellulose, microcrystalline	53.4 mg
calcium hydrogen phosphate dihydrate	18.0 mg
25 sodium starch glycollate	6.0 mg
magnesium stearate	0.4 mg
colloidal anhydrous silica	0.2 mg

35

40

Coating

30 Methylhydroxypropyl cellulose	1.5 mg
cellulose, microcrystalline	0.3 mg
stearic acid	0.6 mg
45 titanium dioxide E 171	0.6 mg

45

35

50

55

PHARMACODYNAMIC AND PHARMACOKINETIC STUDIES

A clinical trial was performed in patients with overactive bladder to determine the pharmacodynamic and pharmacokinetic effects of different daily doses of (i) the above described tolterodine controlled release capsule (below referred to as TOD), compared with (ii) the above described tolterodine immediate release tablet (below referred to as TIR), and (iii) a placebo capsule (containing sugar spheres only). The trial was performed as a double-blind, double dummy, cross-over trial in 60 patients for three one week periods and six treatments (2, 4, 6 and 8 mg TOD once daily, 2 mg TIR twice daily, and placebo). All patients were randomised to three out of six treatments, meaning that 30 patients were subjected to each of the treatments. Pharmacodynamic and pharmacokinetic measurements were performed on day seven in each treatment period. The determinations included measurements of (i) serum concentrations of tolterodine and its main 5-hydroxymethyl metabolite (below called 5-HM) over time, (ii) salivation (dry mouth), and (iii) residual urine volumes.

Serum concentrations of tolterodine and main metabolite

Blood samples were drawn immediately before dosing and after 0.5, 1, 2, 3, 6, 9, 12, 24 and 25 hours, and the free (unbound) serum concentrations of tolterodine and its 5-HM metabolite were measured by gas chromatography/mass spectrometry. The unbound concentrations were calculated assuming a fraction unbound of 3.7% for tolterodine and of 36% for 5-HM as obtained from protein binding studies on human serum (Nilvebrant, L., et al., Life Sciences, Vol. 60, Nos. 13/14 (1997) 1129-1136). Figure 1 shows the obtained variation with time of the sum of the unbound concentrations of tolterodine and 5-HM (which sum is referred to as "active moiety") for, on the one hand, the administration of a 4 mg TOD capsule once daily, and, on the other hand, the administration of a 2 mg TIR tablet

twice daily (i.e. equivalent 24-hour doses of capsule and tablet). As shown in the Figure, the peaks obtained with the TIR tablet are eliminated with the TOD capsule, the latter thus providing a substantially constant serum concentration of active moiety during the 24 hours illustrated.

The difference in fluctuation of the serum concentrations between TIR tablet and TOD capsule may also be demonstrated by calculation of the "fluctuation index". The fluctuation index, FI, is calculated as $FI = (C_{max} - C_{min}) / AUC_{\tau} / \tau$, where τ is the length of the dosage interval and AUC_{τ} is the area under the serum concentration profile during a dosage interval. Thus, the mean calculated fluctuation index for the active moiety was 2.40 (95% CI 1.95-2.63) for the TIR tablet (based on $n=28$), and 0.68 (95% CI 0.59-0.78) for the TOD capsule.

Salivation (dry mouth)

Salivation was measured using dental cotton rolls applied in the mouth for 3 x 2 minutes. Measurements were performed before breakfast and thereafter after each blood sample on day seven in each treatment period. Based on all measurements after dosing, the mean salivation during 12 hours was calculated. The basal salivation at steady state was measured after treatment with (i) 4 mg TOD capsule, (ii) 2 mg TIR tablet, and (iii) placebo. The results are presented in Figure 2. As can be seen in the Figure, the salivation is substantially constant during the period shown for the TOD capsule, whereas a considerable reduction in salivation (i.e. drier mouth) is obtained with the TIR tablet.

While Fig. 2 shows the total salivation as measured, the degree of salivation, or dry mouth, was also determined, based on the patient's estimate of experienced intensity of the phenomenon. The results for 2 mg TIR tablet b.i.d., 4 mg TOD capsule, 6 mg TOD capsule and 8 mg TOD capsule, are presented in bar chart form in Figure 3.

5 The four bars for each dosage represent, from left to right
in the figure, no dry mouth, mild, moderate, and severe,
respectively.

10 As apparent from Fig. 2, the dry mouth intensity for
5 the TIR 2 mg b.i.d. tablet is clearly higher than that of
the TOD 4 mg capsule, and about twice that dosage, i.e. TOD
8 mg, is required to match the adverse dry mouth effects of
the TIR 2 mg b.i.d. tablet.

15 The results from the salivation determinations thus
10 show that flattening of the concentration peaks of the
"active moiety" (i.e. tolterodine plus 5-HM) leads to a
substantial reduction of the undesired dry mouth effect.

20 Residual urine volume

15 Residual volume is the volume of urine left in the
bladder immediately after voiding. Measuring residual
25 volume offers a method of assessing the effect of
antimuscarinic treatment on the bladder. In fact, it offers
a measure of efficacy (change in residual volume) as well
20 as safety (urinary retention, i.e. inability to pass
urine). Efficacy may thus be measured as the mean residual
30 volume per unit of time, and safety as any case where the
residual urine exceeds a fixed level. The mean residual
volume per micturition was measured by a non-invasive
35 (ultrasonic) method for placebo, TIR tablet 2 mg b.i.d.,
25 and for capsules TOD 2 mg, TOD 4 mg, TOD 6 mg, and TOD 8
mg.

The results are presented in Tables 1 and 2 below.
40 Table 1 shows the mean residual volume per micturition, and
30 Table 2 shows the maximum residual volume during 12 hours.

The results presented clearly demonstrate that the TOD
capsule dosages are as efficacious as the corresponding TIR
45 b.i.d dosages, and also that the TOD dose may be increased
up to 8 mg daily and still be safe with regard to urinary
35 retention.

50

55

Table 1

Mean Residual Volume per micturition (ml)

	Placebo	TIR 2mg b.i.d	TOD 2mg	TOD 4mg	TOD 6mg	TOD 8mg
Estimated mean	29	62	40	59	69	77
95% confidence interval	12 to 46	45 to 79	26 to 55	51 to 66	60 to 78	65 to 89
Estimated difference vs. IR			-22	-4	7	14
			-44 to 1	-23 to 15	-13 to 26	-7 to 36

Table 2

Maximum Residual Volume during 12 hours

	Placebo	TIR 2mg b.i.d	TOD 2mg	TOD 4mg	TOD 6mg	TOD 8mg
Median value (ml)	46	72	45	55	87	77
min-max	5-267	10- 316	0-192	0-349	0-360	0-390

The results from the clinical trial described above demonstrate that a flatter serum concentration of active moiety (tolterodine plus 5-HM) not only does not lead to a loss of efficacy or to untoward side-effects, primarily urinary retention, but, importantly, also provides for a reduced dry mouth effect (unaffected or less reduced salivation).

EXAMPLE 2

TOLTERODINE TRANSDERMAL PATCH FORMULATION

Tolterodine-releasing patches were prepared as follows:

5

System 1 (drug-in-adhesive, acrylate)

5 g of tolterodine base were dissolved in 11 g of ethanol and added to 20 g of Durotak 387-2287 (National Starch & Chemical, U.S.A.). The drug gel was coated onto a backing membrane (Scotchpak 1012; 3M Corp., U.S.A.) by using a coating equipment (RK Print Coat Instr. Ltd, Type KCC 202 control coater). The wet layer thickness was 400 μm . The laminate was dried for 20 min. at RT and then for 30 min. at 40°C. A polyester release liner (S 2016; Rexam Release) was laminated onto the dried drug gel. The sheet was cut into patches and stored at 2-8°C until use (packed in Barex pouches). The concentration of tolterodine base in the patches was 2,5 mg/cm².

System 2 (multi-laminate, acrylate)

5 g of tolterodine base were dissolved in 10 ml of ethanol. A mix of 6,4 g of Eudragit RL 100 (Röhm GmbH Chemische Fabrik, Germany) and 6,4 of ethanol and a mix of 2,6 g of Polyvidone 90 (BASF, Germany) and 10,2 g of ethanol were added to the solution of tolterodine base in ethanol. Finally, 4 g of propylene glycol were added. The drug gel was coated onto a backing membrane (Scotchpak 1109; 3M Corp., U.S.A.) by using the coating equipment above. The wet layer thickness was 400 μm . The laminate was then dried at 40°C for 2 hours. An adhesive layer consisting of Plastoid E35H was coated onto a polyester film (S 2016; Rexam Release) and dried at 80°C for 10 min. The two layers were thereafter laminated. The sheet was cut into patches and stored at 2-8°C until use (packed in Barex pouches). The concentration of tolterodine base in the patches was 2,0 mg/cm².

System 3 (multi-laminate, water-based acrylate)

1 g of tolterodine base was mixed with Tween 80 (Merck) by heating to 60 - 70°C. 1,8 g of triethylacetate and 1,3 g of dem. water was added to the mix. The final mix was then added to 25 g of Eudragit RL 30 D (Röhm GmbH Chemische Fabrik, Germany). Finally, 180 mg of 1 N NaOH

55

5 were added. The drug gel was coated onto a backing membrane
(Scotchpak 1109; 3M Corp., U.S.A.) by using the coating
equipment. The wet layer thickness was 400 μm . The laminate
10 was dried at 40°C for 2 hours. An adhesive layer consisting
5 of Plastoid E35H was coated onto a polyester film (S 2016;
Rexam Release) and dried at 80°C for 10 min. The two layers
were thereafter laminated. The sheet was cut into patches
15 and stored at 2-8°C until use (packed in Barex pouches).
The concentration of tolterodine base in the patches was
10 0,5 mg/cm².

Claims

5

10

15

20

25

30

35

40

45

50

55

CLAIMS

1. A method of treating unstable or overactive urinary bladder, wherein the method comprises administering to a patient in need of such treatment tolterodine or a tolterodine-related compound, or a pharmaceutically acceptable salt thereof, in a pharmaceutically effective amount thereof through a controlled release formulation that administers tolterodine or said tolterodine-related compound, or salt thereof, at a controlled rate for at least 24 hours.
2. The method according to claim 1, wherein the formulation is capable of maintaining a substantially constant serum level of the active moiety or moieties for said at least 24 hours.
3. The method according to claim 2, wherein the controlled release formulation provides a mean fluctuation index of said serum level of active moiety or moieties that is not higher than about 2.0, preferably not higher than about 1.0, said fluctuation index, FI, being defined as $FI = (C_{max} - C_{min}) / AUC_t / \tau$, wherein C_{max} and C_{min} are the maximum and minimum concentrations, respectively, of active moiety or moieties, AUC_t is the area under the serum concentration profile, and τ is the length of the dosage interval.
4. The method according to claim 1, 2 or 3, wherein tolterodine, its 5-hydroxymethyl metabolite or the racemate corresponding to tolterodine is administered, and the 24-hour serum profile, expressed as the AUC of unbound tolterodine and 5-hydroxymethyl metabolite, is from about 5 to about 150 nM*h, preferably from about 10 nM*h to about 120 nM*h.
5. The method according to claim 1, 2 or 3, wherein tolterodine, its 5-hydroxymethyl metabolite or the racemate corresponding to tolterodine is administered, and the serum

level of unbound tolterodine and 5-hydroxymethyl metabolite is in the range of about 0.2 to about 6.3 nM, preferably in the range of about 0.4 to about 5.0 nM.

6. The method according to any one of claims 1 to 5, wherein the controlled release formulation is a capsule or tablet for oral administration once daily.

7. The method according to any one of claims 1 to 5, wherein the controlled release formulation is a transdermal preparation, preferably a transdermal patch.

8. The method according to any one of claims 1 to 7, wherein tolterodine is administered.

9. A pharmaceutical formulation containing tolterodine or a tolterodine-related compound, or a pharmaceutically acceptable salt thereof, which formulation when administered to a patient provides controlled release of tolterodine or said tolterodine-related compound, or salt thereof, for at least 24 hours, preferably such that a substantially constant serum level of the active moiety or moieties is maintained for said at least 24 hours.

10. The formulation according to claim 9, which provides a mean fluctuation index of said serum level of active moiety or moieties that is not higher than about 2.0, preferably not higher than about 1.0, said fluctuation index, FI, being defined as $FI = (C_{max} - C_{min}) / AUC_{\tau} / \tau$, wherein C_{max} and C_{min} are the maximum and minimum concentrations, respectively, of active moiety or moieties, AUC_{τ} is the area under the serum concentration profile, and τ is the length of the dosage interval.

11. The formulation according to claim 9 or 10, wherein tolterodine, its 5-hydroxymethyl metabolite or the racemate corresponding to tolterodine is administered, and the 24-hour serum profile, expressed as the AUC of unbound

tolterodine and 5-hydroxymethyl metabolite, is from about 5 to about 150 nM*h, preferably from about 10 nM*h to about 120 nM*h.

12. The formulation according to claim 9 or 10, wherein tolterodine, its 5-hydroxymethyl metabolite or the racemate corresponding to tolterodine is administered, and the serum level of unbound tolterodine and 5-hydroxymethyl metabolite is in the range of about 0.2 to about 6.3 nM, preferably in the range of about 0.4 to about 5.0 nM.

13. The formulation according to any one of claims 9 to 12, which is a capsule or tablet for oral administration once daily.

14. The formulation according to any one of claims 1 to 12, which is a transdermal preparation, preferably a transdermal patch.

15. The formulation according to any one of claims 9 to 14, which provides controlled release of tolterodine.

16. Use of tolterodine or a tolterodine-related compound, or a pharmaceutically acceptable salt thereof, for the manufacture of a therapeutical formulation for treating unstable or overactive urinary bladder, which formulation provides controlled release of tolterodine or said tolterodine-related compound, or salt thereof, for at least 24 hours, preferably such that a substantially constant serum level of the active moiety or moieties is maintained for said at least 24 hours.

17. The use according to claim 16, wherein a formulation according to any one of claims 10 to 15 is manufactured.

18. A method for providing a continuous plasma concentration of tolterodine-related active moiety in a patient, wherein the method comprises administering a

5

10

dosage form formulation comprising tolterodine or a
tolterodine-related compound, or a pharmaceutically
acceptable salt thereof, that is administered over at least
24 hours to the patient at a controlled and sustained rate
5 to provide the desired plasma active moiety concentration.

15

19. The method according to claim 18, wherein the dosage
form formulation is administered orally.

20

25

30

35

40

45

50

55

AMENDED CLAIMS

[received by the International Bureau on 10 February 2000 (10.02.00);
original claims 1-19 replaced by new claims 1-17 (3 pages)]

1. A method of treating unstable or overactive urinary bladder, wherein the method comprises administering to a patient in need of such treatment tolterodine or a tolterodine-related compound, or a pharmaceutically acceptable salt thereof, in a pharmaceutically effective amount thereof through a controlled release formulation capable of maintaining a substantially constant serum level of the active moiety or moieties for at least 24 hours.

2. The method according to claim 1, wherein the controlled release formulation provides a mean fluctuation index of said serum level of active moiety or moieties that is not higher than about 2.0, preferably not higher than about 1.0, said fluctuation index, FI, being defined as $FI = (C_{max} - C_{min}) / AUC_{\tau} / \tau$, wherein C_{max} and C_{min} are the maximum and minimum concentrations, respectively, of active moiety or moieties, AUC_{τ} is the area under the serum concentration profile, and τ is the length of the dosage interval.

3. The method according to claim 1 or 2, wherein tolterodine, its 5-hydroxymethyl metabolite or the racemate corresponding to tolterodine is administered, and the 24-hour serum profile, expressed as the AUC of unbound tolterodine and 5-hydroxymethyl metabolite, is from about 5 to about 150 nM*h, preferably from about 10 nM*h to about 120 nM*h.

4. The method according to claim 1, 2 or 3, wherein tolterodine, its 5-hydroxymethyl metabolite or the racemate corresponding to tolterodine is administered, and the serum level of unbound tolterodine and 5-hydroxymethyl metabolite is in the range of about 0.2 to about 6.3 nM, preferably in the range of about 0.4 to about 5.0 nM.

5. The method according to any one of claims 1 to 4, wherein the controlled release formulation is a capsule or tablet for oral administration once daily.

6. The method according to any one of claims 1 to 4, wherein the controlled release formulation is a transdermal preparation, preferably a transdermal patch.

7. The method according to any one of claims 1 to 6, wherein tolterodine is administered.

8. The method according to any one of claims 1 to 6, wherein urinary incontinence is treated.

9. A pharmaceutical formulation containing tolterodine or a tolterodine-related compound, or a pharmaceutically acceptable salt thereof, which formulation when administered to a patient provides controlled release of tolterodine or said tolterodine-related compound, or salt thereof, such that a substantially constant serum level of the active moiety or moieties is maintained for at least 24 hours.

10. The formulation according to claim 9, which provides a mean fluctuation index of said serum level of active moiety or moieties that is not higher than about 2.0, preferably not higher than about 1.0, said fluctuation index, FI, being defined as $FI = (C_{max} - C_{min}) / AUC_{\tau} / \tau$, wherein C_{max} and C_{min} are the maximum and minimum concentrations, respectively, of active moiety or moieties, AUC_{τ} is the area under the serum concentration profile, and τ is the length of the dosage interval.

11. The formulation according to claim 9 or 10, wherein tolterodine, its 5-hydroxymethyl metabolite or the racemate corresponding to tolterodine is administered, and the 24-hour serum profile, expressed as the AUC of

unbound tolterodine and 5-hydroxymethyl metabolite, is from about 5 to about 150 nM*h, preferably from about 10 nM*h to about 120 nM*h.

12. The formulation according to claim 9 or 10, wherein tolterodine, its 5-hydroxymethyl metabolite or the racemate corresponding to tolterodine is administered, and the serum level of unbound tolterodine and 5-hydroxymethyl metabolite is in the range of about 0.2 to about 6.3 nM, preferably in the range of about 0.4 to about 5.0 nM.

13. The formulation according to any one of claims 9 to 12, which is a capsule or tablet for oral administration once daily.

14. The formulation according to any one of claims 1 to 12, which is a transdermal preparation, preferably a transdermal patch.

15. The formulation according to any one of claims 9 to 14, which provides controlled release of tolterodine.

16. Use of tolterodine or a tolterodine-related compound, or a pharmaceutically acceptable salt thereof, for the manufacture of a therapeutical formulation for treating unstable or overactive urinary bladder, which formulation provides controlled release of tolterodine or said tolterodine-related compound, or salt thereof, such that a substantially constant serum level of the active moiety or moieties is maintained for at least 24 hours.

17. The use according to claim 16, wherein a formulation according to any one of claims 10 to 15 is manufactured.




FIG. 1




FIG. 2

2/2




FIG. 3

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE 99/01463

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: A61K 9/22, A61K 9/52, A61K 9/70, A61K 31/135, A61P 13/10
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: A61K, A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAPLUS, WPI, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 9803067 A1 (ABERG, GUNNAR), 29 January 1998 (29.01.98), abstract, second paragraph on page 4, third paragraph on page 5 and claims 12 and 13 --	1-19
A	WO 9811888 A1 (AMERICAN HOME PRODUCTS CORPORATION), 26 March 1998 (26.03.98), page 3, line 5; page 3, line 20 - line 25 --	1-19
A	WO 9612477 A1 (LEIRAS OY), 2 May 1996 (02.05.96) --	1-19
A	WO 9323025 A1 (ALZA CORPORATION), 25 November 1993 (25.11.93) -- -----	1-5,7-12, 14-18

☐ Further documents are listed in the continuation of Box C. ☒ See patent family annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "I" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"I" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

21 December 1999

Date of mailing of the international search report

19 January 2000 (19.01.00)

Name and mailing address of the ISA

Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. +46 8 666 02 86

Authorized officer

Anneli Jönsson / MR
Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE 99/01463

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 1-8, 18-19
because they relate to subject matter not required to be searched by this Authority, namely:
see extra sheet
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE 99/01463

Remark: Claims 1-8, 18-19 are directed to methods of treatment of the human or animal body by therapy methods practised on the human or animal body/Rule 39.1(iv) Nevertheless a search has been executed for these claims. The search has been based on the alleged effects of the compositions.

INTERNATIONAL SEARCH REPORT

02/12/99

International application No.
PCT/SE 99/01463

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9803067 A1	29/01/98	AU 3725997 A CA 2259012 A EP 0924983 A	10/02/98 29/01/98 30/06/99
WO 9811888 A1	26/03/98	AU 4421697 A EP 0927034 A	14/04/98 07/07/99
WO 9612477 A1	02/05/96	AU 7994694 A	15/05/96
WO 9323025 A1	25/11/93	AT 185694 T AU 666735 B AU 4247393 A CA 2132865 A DE 69326848 D EP 0767659 A,B FI 945311 A JP 8502952 T MX 9302812 A NO 944249 A NZ 252598 A US 5411740 A US 5500222 A US 5900250 A ZA 9303349 A	15/11/99 22/02/96 13/12/93 25/11/93 00/00/00 16/04/97 11/11/94 02/04/96 01/11/93 14/11/94 29/01/97 02/05/95 19/03/96 04/05/99 15/06/94